Regeneron Pharmaceuticals, Inc announced that the US Food and Drug Administration (FDA) has approved Eylea (aflibercept) injection to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness.
Regeneron Pharmaceuticals, Inc announced that the US Food and Drug Administration (FDA) has approved Eylea (aflibercept) injection to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
